Please assess the completion status of the following clinical trial:

Trial Title: Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~* Diagnosis of systemic mastocytosis per 2008 World Health Organization (WHO) criteria. Those with advanced systemic mastocytosis (ASM); mast cell leukemia (MCL); or systemic mastocytosis-associated hematological clonal non-mast cell lineage disease (SM-AHNMD) required to have at least 1 organ damage finding~* Serum aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3.0 x upper limit of normal (ULN); if considered related to ASM/MCL ≤ 5 x ULN~* Estimated creatinine clearance ≥ 30 mL/min (Cockcroft-Gault)~* Total bilirubin ≤ 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin); if considered related to ASM/MCL ≤ 3 x ULN~* Female subjects must be of non-reproductive potential, or if of childbearing potential must have a negative serum pregnancy test upon study entry~* Must agree to use highly effective methods of birth control~* Written informed consent~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 3~* Life expectancy \> 12 weeks~EXCLUSION CRITERIA~* Received any investigational agent, chemotherapy, interferon-alpha, or 2-chlorodeoxyadenosine (2-CdA, cladribine) within 30 days prior to day 1; or monoclonal antibody ≤ 6 weeks prior to first administration of study treatment (patients with an AHNMD with progressive leukocytosis who require control of their counts are permitted to receive hydroxyurea)~* Diagnosis of AHNMD requiring immediate cytoreductive therapy or targeted drugs (eg, acute myeloid leukemia \[AML\])~* History of other malignancies, except:~  * Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before the first dose of study drug, and at low risk for recurrence~ * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease~ * Adequately treated carcinoma in situ without evidence of disease~* Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration \[\> 14 days\] of \> 10 mg/day of prednisone) within 28 days of the first dose of study drug~* Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug~* Systemic treatment for infection completed ≤ 14 days before the first dose of study drug~* Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (CTCAE, version 4), grade 0 or 1, or to the levels dictated in the inclusion/exclusion criteria with the exception of alopecia~* Known bleeding disorders (eg, severe von Willebrand's disease) or severe hemophilia~* History of stroke or intracranial hemorrhage within 6 months prior to enrollment~* Known history of human immunodeficiency virus (HIV) or~* Active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV)~* Major surgery within 4 weeks of first dose of study drug~* Any life-threatening illness, medical condition, or organ system dysfunction that could compromise the subject's safety or put the study outcomes at undue risk~* Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization~* Unable to swallow capsules or malabsorption syndrome~* Disease significantly affecting gastrointestinal function~* Resection of the stomach or small bowel~* Symptomatic inflammatory bowel disease~* Ulcerative colitis~* Partial or complete bowel obstruction~* Requires treatment with a strong cytochrome P450 (CYP) 3A4/5 inhibitor~* Lactating or pregnant~* Unwilling or unable to participate in all required study evaluations and procedures~* Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations)~* Known hypersensitivity to any excipient contained in the drug~* Received hematopoietic growth factor support within 14 days of day 1 of ibrutinib (Jehovah's witnesses may be given an erythropoiesis-stimulating agent before and during the trial in lieu of red blood cell transfusions but anemia and/or red blood cell (RBC) transfusion dependence cannot be used for response assessment in these patients)~* Presence of the factor interacting with poly(A) polymerase alpha (PAPOLA) and cleavage and polyadenylation specific factor 1 (CPSF1) (FIP1L1)-platelet-derived growth factor receptor, alpha polypeptide (PDGFRalpha) fusion even with resistance to imatinib (such patients are no longer defined as systemic mastocytosis by the WHO)~* Received any treatment with ibrutinib prior to study entry~* The concomitant use of warfarin or other vitamin K antagonists unless felt to be of significant clinical need; low molecular weight heparin or other anticoagulants may be used instead if anticoagulation is required

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ibrutinib 420 mg/day (Type: EXPERIMENTAL): Participants receive ibrutinib daily on days 1 to 28, at 420 mg/day in 28-day cycles
- Ibrutinib 560 mg/day (Type: EXPERIMENTAL): Participants receive ibrutinib daily on days 1 to 28, at 560 mg/day in 28-day cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues